Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm

This article was originally published in The Tan Sheet

Executive Summary

Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1

Related Content

‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
With Democrat In White House, “More Aggressive” FDA Comes Into Focus
NDAC Meeting On Actual-Use Trials Scheduled For September
NDAC Chair
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
Alli Sparks Reevaluation Of OTC Weight-Loss Indication
Primatene Mist Availability Not “Essential,” Advisory Panel Says
Antiseptic Log Reduction Criteria Should Stand, NDAC Recommends
Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says
Mevacor Daily Regimen Compliance Questioned By FDA Committees





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts